Okumist 0.01% dropper bottle eye drops 10 ml

Ophthalmology
Okumistin®, eye, ear, and nasal drops are recommended for use in the complex treatment of infectious processes of the anterior segment of the eye (blepharitis, conjunctivitis, keratitis, keratouveitis), eye injuries, eye burns (thermal and chemical); in the preoperative and postoperative periods for the treatment and prevention of purulent-inflammatory eye lesions. Prevention of ophthalmia in newborns, including gonococcal and chlamydial.
Otorhinolaryngology
The drug is used in the complex treatment of acute sinusitis/rhinosinusitis, exacerbation of chronic sinusitis/rhinosinusitis, acute rhinitis; acute and chronic external otitis, chronic purulent mesotympanitis, otomycosis.

Ophthalmology
Locally. For adults, for therapeutic purposes, the drug Okimistin® is instilled into the conjunctival sac at a dose of 1-2 drops 4-6 times a day until clinical recovery.
For prophylactic purposes, the drug is instilled 2-3 days before surgery, as well as for 10-15 days after surgery at a dose of 1-2 drops 3 times a day.
When treating eye burns, after rinsing the eye with a large amount of water, frequent instillations (every 5-10 minutes) are performed for 1-2 hours. For further treatment, the drug is used at a dose of 1-2 drops 4-6 times a day.
In pediatric practice, for the treatment of bacterial conjunctivitis in children, the drug Okimistin® is instilled into the conjunctival sac at a dose of 1 drop up to 6 times a day for 7-10 days.
To prevent ophthalmia in newborns, immediately after birth, 1 drop of the drug is instilled into each eye 2 times with an interval of 2-3 minutes.

Otorhinolaryngology
Locally. For adults with acute sinusitis/rhinosinusitis, exacerbation of chronic sinusitis/rhinosinusitis, acute rhinitis, and infection of the nasal mucosa, the drug Okimistin® is instilled at a dose of 2-3 drops in each nostril, 4-6 times a day. The treatment course lasts up to 14 days.
In pediatric practice, for the treatment of acute rhinosinusitis and exacerbation of chronic rhinosinusitis in children over 1 year old, the drug Okimistin® is instilled in each nasal passage at a dose of 1-2 drops up to 4-6 times a day for 10-14 days.
For adults. Locally.
In cases of acute and chronic external otitis, otomycosis, the drug Okimistin® is instilled into the external auditory canal at a dose of 5 drops 4 times a day or, instead of instillation, a gauze turunda soaked with the drug is inserted into the external auditory canal 4 times a day. The treatment course lasts 10 days.
In adults with chronic mesotympanitis, it is used in combination therapy with ultrasonic irrigation or administration into the tympanic cavity along with antibiotics.
If there is no positive dynamics (increased severity or appearance of new signs/symptoms of the disease, development of complications) on the 3rd-4th day of therapy using the drug Okimistin®, it is necessary to consult a doctor!

Active ingredient:
Benzildimethyl[3-(myristoylamino)propyl]ammonium chloride monohydrate (calculated as anhydrous substance) - 0.01 g
Excipients: sodium chloride - 0.90 g,
purified water to 100 ml

Colorless transparent liquid.

Contraindications
Individual sensitivity to the components of the drug.

Contact lenses should be removed immediately before instilling the Ocomistin® solution and can be reinserted no earlier than 15 minutes after instillation. To avoid contamination and cross-infection, do not use one bottle for the simultaneous treatment of infections of the eye, nose, and/or ear. To prevent contamination of the solution during instillation, patients should avoid contact between the tip of the dropper and the eye or skin. Sharing the dropper bottle with more than one person may lead to the spread of infection.
Children
The product can be used in pediatric practice.

Use during pregnancy and breastfeeding
The use of the product during pregnancy and breastfeeding is possible only if the expected benefit to the mother outweighs the potential risk to the fetus and child.

Allergic reactions are possible. In some cases, a slight burning sensation or discomfort may occur, which resolves on its own within 15-20 seconds and does not require discontinuation of the medication.
If any undesirable effects occur, it is necessary to consult a doctor.

Not observed

When used in combination, Ocomistin® enhances the effectiveness of local antibiotics.
Studies on the interaction of the drug with other medications have not been conducted.

The active ingredient of Ocomistin® is the antiseptic Benzildimethyl-myristoylamino-propylammonium, which exhibits pronounced antimicrobial activity against gram-positive and gram-negative, aerobic and anaerobic bacteria in both monocultures and microbial associations, including hospital strains with multidrug resistance to antibiotics. The product acts on chlamydia, pathogenic fungi, as well as herpes viruses and adenoviruses. The product is more effective against gram-positive bacteria, including: staphylococci, streptococci. It has antifungal activity against ascomycetes of the genera Aspergillus and Penicillium, yeasts (Rhodotorula tubra, Torulopsis glabrata) and yeast-like fungi (Trichophyton rubrum, Trichophyton mentagrophytes, Trichophyton verrucosum, T. schoenleini, T. violaceum, Epidermophyton Kaufman-Wolf, E. floccosum, Microsporum gypseum, Microsporum canis), as well as other pathogenic fungi (for example, Pityrosporum orbiculare (Malassezia furfur)) in both monocultures and microbial associations, including fungal microflora resistant to chemotherapeutic agents.

The action of Benzildimethyl-myristoylamino-propylammonium is based on the direct hydrophobic interaction of the molecule with the lipids of microbial membranes, leading to their fragmentation and destruction. In this process, part of the Benzildimethyl-myristoylamino-propylammonium molecule penetrates the hydrophobic region of the membrane, disrupting the supramembrane layer, loosening the membrane, increasing its permeability to macromolecules, altering the enzymatic activity of the microbial cell, and inhibiting enzyme systems, which results in the suppression of microbial viability and their cytolysis. Benzildimethyl-myristoylamino-propylammonium has a high selectivity of action against microorganisms, as it practically does not affect human cell membranes, which is related to the different structure of the latter - significantly longer lipid radicals that sharply limit the possibility of hydrophobic interaction of Benzildimethyl-myristoylamino-propylammonium with cells. Under the influence of the product, the resistance of bacteria and fungi to antibiotics decreases. Benzildimethyl-myristoylamino-propylammonium possesses anti-inflammatory and immunoadjuvant effects, enhances local protective reactions, regenerative processes, and activates mechanisms of nonspecific defense due to modulation of cellular and local humoral immune responses.

The drug exerts a local effect. Data on possible penetration into the bloodstream is absent.